Which has better valuation & earnings, PDSB or KZIA?

Novogen has higher revenue and earnings than PDS Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A Novogen $30K 4,491.94 -$13.41M N/A N/A

Is PDSB or KZIA more profitable?

Novogen's return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -708.18% -136.50% Novogen N/A N/A N/A

Does the media favor PDSB or KZIA?

In the previous week, PDS Biotechnology had 9 more articles in the media than Novogen. MarketBeat recorded 10 mentions for PDS Biotechnology and 1 mentions for Novogen. PDS Biotechnology's average media sentiment score of 0.53 beat Novogen's score of 0.34 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PDSB or CRBU?

In the previous week, PDS Biotechnology had 6 more articles in the media than Caribou Biosciences. MarketBeat recorded 10 mentions for PDS Biotechnology and 4 mentions for Caribou Biosciences. PDS Biotechnology's average media sentiment score of 0.53 beat Caribou Biosciences' score of 0.14 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADCT or PDSB?

In the previous week, PDS Biotechnology had 9 more articles in the media than ADC Therapeutics. MarketBeat recorded 10 mentions for PDS Biotechnology and 1 mentions for ADC Therapeutics. PDS Biotechnology's average media sentiment score of 0.53 beat ADC Therapeutics' score of 0.51 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PDSB or EQ more profitable?

Equillium's return on equity of -41.15% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -708.18% -136.50% Equillium N/A -41.15% -38.29%

Does the media refer more to PDSB or EQ?

In the previous week, PDS Biotechnology had 5 more articles in the media than Equillium. MarketBeat recorded 10 mentions for PDS Biotechnology and 5 mentions for Equillium. PDS Biotechnology's average media sentiment score of 0.53 beat Equillium's score of -0.11 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, HURA or PDSB?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.54 N/A PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A

Is HURA or PDSB more profitable?

TuHURA Biosciences' return on equity of -156.47% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% PDS Biotechnology N/A -708.18% -136.50%

Does the media prefer HURA or PDSB?

In the previous week, PDS Biotechnology had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 10 mentions for PDS Biotechnology and 7 mentions for TuHURA Biosciences. PDS Biotechnology's average media sentiment score of 0.53 beat TuHURA Biosciences' score of 0.37 indicating that PDS Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PDS Biotechnology (PDSB) Competitors

$0.81 -0.04 (-4.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.83 +0.02 (+2.55%)

As of 09/18/2026 07:59 PM Eastern

Compare

PDSB vs. KZIA, CRBU, ADCT, EQ, and HURA

Should you buy PDS Biotechnology stock or one of its competitors? PDS Biotechnology's main competitors and comparable companies include Novogen (KZIA), Caribou Biosciences (CRBU), ADC Therapeutics (ADCT), Equillium (EQ), and TuHURA Biosciences (HURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PDS Biotechnology compare to Novogen?

PDS Biotechnology (NASDAQ:PDSB) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PDS Biotechnology currently has a consensus price target of $9.00, indicating a potential upside of 1,017.32%. Novogen has a consensus price target of $27.33, indicating a potential upside of 163.07%. Given PDS Biotechnology's higher possible upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Novogen's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Novogen	N/A	N/A	N/A

In the previous week, PDS Biotechnology had 9 more articles in the media than Novogen. MarketBeat recorded 10 mentions for PDS Biotechnology and 1 mentions for Novogen. PDS Biotechnology's average media sentiment score of 0.53 beat Novogen's score of 0.34 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novogen has higher revenue and earnings than PDS Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Novogen	$30K	4,491.94	-$13.41M	N/A	N/A

PDS Biotechnology has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Summary

Novogen beats PDS Biotechnology on 8 of the 12 factors compared between the two stocks.

How does PDS Biotechnology compare to Caribou Biosciences?

PDS Biotechnology (NASDAQ:PDSB) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

PDS Biotechnology has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 1,017.32%. Caribou Biosciences has a consensus target price of $7.75, suggesting a potential upside of 496.15%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PDS Biotechnology has higher earnings, but lower revenue than Caribou Biosciences. PDS Biotechnology is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Caribou Biosciences	$11.16M	12.49	-$148.12M	-$1.08	N/A

PDS Biotechnology has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market.

In the previous week, PDS Biotechnology had 6 more articles in the media than Caribou Biosciences. MarketBeat recorded 10 mentions for PDS Biotechnology and 4 mentions for Caribou Biosciences. PDS Biotechnology's average media sentiment score of 0.53 beat Caribou Biosciences' score of 0.14 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Caribou Biosciences beats PDS Biotechnology on 10 of the 16 factors compared between the two stocks.

How does PDS Biotechnology compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

PDS Biotechnology has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.66	-$142.62M	-$0.66	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

ADC Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 373.93%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 1,017.32%. Given PDS Biotechnology's higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
PDS Biotechnology	N/A	-708.18%	-136.50%

ADC Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, PDS Biotechnology had 9 more articles in the media than ADC Therapeutics. MarketBeat recorded 10 mentions for PDS Biotechnology and 1 mentions for ADC Therapeutics. PDS Biotechnology's average media sentiment score of 0.53 beat ADC Therapeutics' score of 0.51 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PDS Biotechnology beats ADC Therapeutics on 8 of the 14 factors compared between the two stocks.

How does PDS Biotechnology compare to Equillium?

PDS Biotechnology (NASDAQ:PDSB) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, PDS Biotechnology had 5 more articles in the media than Equillium. MarketBeat recorded 10 mentions for PDS Biotechnology and 5 mentions for Equillium. PDS Biotechnology's average media sentiment score of 0.53 beat Equillium's score of -0.11 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Equillium has higher revenue and earnings than PDS Biotechnology. Equillium is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Equillium	$41.10M	2.96	-$22.40M	-$0.20	N/A

PDS Biotechnology has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Equillium has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Equillium's return on equity of -41.15% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Equillium	N/A	-41.15%	-38.29%

PDS Biotechnology presently has a consensus price target of $9.00, indicating a potential upside of 1,017.32%. Equillium has a consensus price target of $7.57, indicating a potential upside of 294.35%. Given PDS Biotechnology's higher possible upside, equities research analysts plainly believe PDS Biotechnology is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Equillium beats PDS Biotechnology on 11 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

TuHURA Biosciences has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

In the previous week, PDS Biotechnology had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 10 mentions for PDS Biotechnology and 7 mentions for TuHURA Biosciences. PDS Biotechnology's average media sentiment score of 0.53 beat TuHURA Biosciences' score of 0.37 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 328.57%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 1,017.32%. Given PDS Biotechnology's higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

TuHURA Biosciences' return on equity of -156.47% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
PDS Biotechnology	N/A	-708.18%	-136.50%

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

PDS Biotechnology beats TuHURA Biosciences on 7 of the 13 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$45.08M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-1.26	14.23	275.49	25.40
Price / Sales	N/A	1,439.65	644.37	87.46
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	4.48	15.45	10.46	6.33
Net Income	-$34.50M	-$22.86M	$3.49B	$358.33M
7 Day Performance	173.14%	-1.21%	0.59%	1.12%
1 Month Performance	285.59%	-3.29%	-1.74%	-2.39%
1 Year Performance	-23.29%	37.74%	18.13%	5.35%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	2.6905 of 5 stars	$0.81 -4.4%	$9.00 +1,017.3%	-23.3%	$45.08M	N/A	N/A	21	Analyst Upgrade Gap Down
KZIA Novogen	3.2979 of 5 stars	$10.55 -5.5%	$27.33 +159.2%	+33.9%	$137.11M	$30K	N/A	12	Short Interest Increase
CRBU Caribou Biosciences	2.092 of 5 stars	$1.27 -1.9%	$7.75 +512.6%	-23.1%	$135.62M	$10.04M	N/A	100	News Coverage Analyst Downgrade
ADCT ADC Therapeutics	2.2468 of 5 stars	$1.04 -6.8%	$5.00 +383.1%	-69.2%	$132.14M	$79.58M	N/A	310	News Coverage
EQ Equillium	2.3408 of 5 stars	$2.03 -3.3%	$7.57 +273.0%	+31.5%	$128.72M	N/A	N/A	40	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. KZIA, CRBU, ADCT, EQ, and HURA

How does PDS Biotechnology compare to Novogen?

Summary

How does PDS Biotechnology compare to Caribou Biosciences?

Summary

How does PDS Biotechnology compare to ADC Therapeutics?

Summary

How does PDS Biotechnology compare to Equillium?

Summary

How does PDS Biotechnology compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. KZIA, CRBU, ADCT, EQ, and HURA

How does PDS Biotechnology compare to Novogen?

Do institutionals & insiders have more ownership in PDSB or KZIA?

Do analysts recommend PDSB or KZIA?

Is PDSB or KZIA more profitable?

Does the media favor PDSB or KZIA?

Which has better valuation & earnings, PDSB or KZIA?

Which has more volatility & risk, PDSB or KZIA?

Summary

How does PDS Biotechnology compare to Caribou Biosciences?

Is PDSB or CRBU more profitable?

Do analysts rate PDSB or CRBU?

Do insiders and institutionals have more ownership in PDSB or CRBU?

Which has higher valuation and earnings, PDSB or CRBU?

Which has more risk and volatility, PDSB or CRBU?

Does the media favor PDSB or CRBU?

Summary

How does PDS Biotechnology compare to ADC Therapeutics?

Which has stronger earnings and valuation, ADCT or PDSB?

Do analysts recommend ADCT or PDSB?

Is ADCT or PDSB more profitable?

Which has more risk & volatility, ADCT or PDSB?

Do institutionals & insiders believe in ADCT or PDSB?

Does the media prefer ADCT or PDSB?

Summary

How does PDS Biotechnology compare to Equillium?

Does the media refer more to PDSB or EQ?

Which has stronger valuation & earnings, PDSB or EQ?

Which has more risk and volatility, PDSB or EQ?

Is PDSB or EQ more profitable?

Do analysts recommend PDSB or EQ?

Do insiders and institutionals have more ownership in PDSB or EQ?

Summary

How does PDS Biotechnology compare to TuHURA Biosciences?

Which has more risk and volatility, HURA or PDSB?

Which has higher valuation and earnings, HURA or PDSB?

Does the media prefer HURA or PDSB?

Do analysts rate HURA or PDSB?

Is HURA or PDSB more profitable?

Do insiders & institutionals hold more shares of HURA or PDSB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools